<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Health Forum</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Health Forum</journal-id><journal-id journal-id-type="pmc-domain-id">3211</journal-id><journal-id journal-id-type="pmc-domain">jamasd</journal-id><journal-title-group><journal-title>JAMA Health Forum</journal-title></journal-title-group><issn pub-type="epub">2689-0186</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>JAMA Network</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12475944</article-id><article-id pub-id-type="pmcid-ver">PMC12475944.1</article-id><article-id pub-id-type="pmcaid">12475944</article-id><article-id pub-id-type="pmcaiid">12475944</article-id><article-id pub-id-type="pmid">41004181</article-id><article-id pub-id-type="doi">10.1001/jamahealthforum.2025.3351</article-id><article-id pub-id-type="publisher-id">aoi250070</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="domain" specific-use="print"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group><subj-group subj-group-type="thematic-label"><subject>AI in Health Policy</subject></subj-group><subj-group subj-group-type="online-only"><subject>Online Only</subject></subj-group><subj-group subj-group-type="allowCommenting"><subject>Comments</subject></subj-group></article-categories><title-group><article-title>Benefit-Risk Reporting for FDA-Cleared Artificial Intelligence&#8722;Enabled Medical Devices</article-title><alt-title alt-title-type="headline">Benefit-Risk Reporting for FDA-Cleared Artificial Intelligence&#8722;Enabled Medical Devices</alt-title><alt-title alt-title-type="running-head">Benefit-Risk Reporting for FDA-Cleared Artificial Intelligence&#8722;Enabled Medical Devices</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Lin</surname><given-names initials="JC">John C.</given-names></name><degrees>BS</degrees><xref rid="aoi250070aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jain</surname><given-names initials="B">Bhav</given-names></name><degrees>BS</degrees><xref rid="aoi250070aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Iyer</surname><given-names initials="JM">Jay M.</given-names></name><degrees>BA</degrees><xref rid="aoi250070aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rola</surname><given-names initials="I">Ishan</given-names></name><degrees>BS</degrees><xref rid="aoi250070aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Srinivasan</surname><given-names initials="AR">Anusha R.</given-names></name><degrees>BS</degrees><xref rid="aoi250070aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kang</surname><given-names initials="C">Chaerim</given-names></name><degrees>AB</degrees><xref rid="aoi250070aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Patel</surname><given-names initials="H">Heta</given-names></name><degrees>MD</degrees><xref rid="aoi250070aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Parikh</surname><given-names initials="RB">Ravi B.</given-names></name><degrees>MD</degrees><degrees>MPP</degrees><xref rid="aoi250070aff6" ref-type="aff">
<sup>6</sup>
</xref><xref rid="aoi250070aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib></contrib-group><aff id="aoi250070aff1"><label>1</label>Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia</aff><aff id="aoi250070aff2"><label>2</label>Department of Medicine, Stanford University School of Medicine, Stanford, California</aff><aff id="aoi250070aff3"><label>3</label>Departments of Molecular and Cellular Biology and Statistics, Harvard University, Cambridge, Massachusetts</aff><aff id="aoi250070aff4"><label>4</label>The Ohio State University College of Medicine, Columbus</aff><aff id="aoi250070aff5"><label>5</label>Division of Biology and Medicine, Brown University, Providence, Rhode Island</aff><aff id="aoi250070aff6"><label>6</label>Emory School of Medicine, Atlanta, Georgia</aff><aff id="aoi250070aff7"><label>7</label>Winship Cancer Institute, Emory University, Atlanta, Georgia</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> May 22, 2025.</p><p content-type="published-online"><bold>Published:</bold> September 26, 2025. doi:<uri content-type="doi">10.1001/jamahealthforum.2025.3351</uri></p><p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. &#169; 2025 Lin JC et al. <italic toggle="yes">JAMA Health Forum</italic>.</p><corresp id="aoi250070cor1"><bold>Corresponding Author:</bold> Ravi B. Parikh, MD, MPP, Department of Hematology and Medical Oncology, Winship Cancer Institute, 1750 Haygood Dr NE, Atlanta, GA 30307 (<email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ravi.bharat.parikh@emory.edu">ravi.bharat.parikh@emory.edu</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Dr Parikh had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p><p><italic toggle="yes">Concept and design:</italic> Lin, Jain, Srinivasan, Parikh.</p><p><italic toggle="yes">Acquisition, analysis, or interpretation of data:</italic> Lin, Jain, Iyer, Rola, Kang, Patel, Parikh.</p><p><italic toggle="yes">Drafting of the manuscript:</italic> Lin, Jain, Iyer, Patel, Parikh.</p><p><italic toggle="yes">Critical review of the manuscript for important intellectual content:</italic> Lin, Jain, Iyer, Rola, Kang, Srinivasan, Parikh.</p><p><italic toggle="yes">Statistical analysis:</italic> Lin, Jain, Iyer, Rola, Parikh.</p><p><italic toggle="yes">Obtained funding:</italic> Parikh.</p><p><italic toggle="yes">Administrative, technical, or material support:</italic> Kang, Srinivasan, Parikh.</p><p><italic toggle="yes">Supervision:</italic> Parikh.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Parikh reported grants from the US National Institutes of Health, US Department of Defense, the Prostate Cancer Foundation, the National Palliative Care Research Center, the National Comprehensive Cancer Network Foundation, Conquer Cancer Foundation, Humana, Emerson Collective, Schmidt Futures, Arnold Ventures, Mendel.ai, and Veterans Health Administration; personal fees and equity from GNS Healthcare, Thyme Care, Main Street Health, Onc.AI, ConcertAI, Cancer Study Group, Mendel.ai, Optinosis, Biofourmis, Archetype Therapeutics, Credit Suisse, G1 Therapeutics, Humana, and NanOlogy; honoraria from Flatiron and Medscape; has board membership (unpaid) at the Coalition to Transform Advanced Care and American Cancer Society; editor at the <italic toggle="yes">Journal of Clinical Oncology</italic>; and serves on a leadership consortium (unpaid) at the National Quality Forum, all outside the submitted work. No other disclosures were reported.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-AOI250070-1-s" ref-type="supplementary-material">Supplement 3</xref>.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2025-09-26T10:00"><day>26</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>6</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">497707</issue-id><elocation-id>e253351</elocation-id><history><date date-type="received"><day>14</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>22</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 20:25:39.430"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright 2025 Lin JC et al. <italic toggle="yes">JAMA Health Forum</italic>.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jamahealthforum-e253351.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf-version" xlink:href="jamahealthforum-e253351.pdf">jamahealthforum-e253351.pdf</self-uri><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="silverchair" xlink:href="https://jamanetwork.com/channels/health-forum/fullarticle/10.1001/jamahealthforum.2025.3351"/><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-aoi250070-1"><title>Question</title><p>How comprehensively are efficacy, safety, and risk assessments reported for artificial intelligence (AI)/machine learning (ML)&#8722;enabled devices cleared by the US Food and Drug Administration (FDA)?</p></sec><sec id="ab-aoi250070-2"><title>Findings</title><p>This cross-sectional study of 691 FDA-cleared AI/ML devices found that key elements were frequently unreported, including study design (323 devices [46.7%]), training sample size (385 [53.3%]), and demographic representation (660 [95.5%]), with only 6 devices (1.6%) reporting data from randomized clinical trials, and 3 (&lt;1%) reporting patient outcomes. Premarket safety assessments were documented for 195 devices (28.2%) and postmarket adverse events, including 1 death, were reported for 36 devices (5.2%).</p></sec><sec id="ab-aoi250070-3"><title>Meaning</title><p>These findings indicate that standardized efficacy, safety, and risk assessment reporting remains inadequate for FDA-cleared AI/ML devices, underscoring the need for dedicated regulatory pathways and robust postmarket surveillance to ensure patient safety.</p></sec></abstract><abstract><sec id="ab-aoi250070-4"><title>Importance</title><p>Devices enabled by artificial intelligence (AI) and machine learning (ML) are increasingly used in clinical settings, but there are concerns regarding benefit-risk assessment and surveillance by the US Food and Drug Administration (FDA).</p></sec><sec id="ab-aoi250070-5"><title>Objective</title><p>To characterize pre- and postmarket efficacy, safety, and risk assessment reporting for FDA-cleared AI/ML devices.</p></sec><sec id="ab-aoi250070-6"><title>Design and Setting</title><p>This was a cross-sectional study using linked data from FDA decision summaries and approvals databases, the FDA Manufacturer and User Facility Device Experience Database, and the FDA Medical Device Recalls Database for all AI/ML devices cleared by the FDA from September 1995 to July 2023. Data were analyzed from October to November 2024.</p></sec><sec id="ab-aoi250070-7"><title>Main Outcomes and Measures</title><p>AI/ML reporting of study design, data availability, efficacy, safety, bias assessments, adverse events, device recalls, and risk classification.</p></sec><sec id="ab-aoi250070-8"><title>Results</title><p>The analysis included data for all 691 AI/ML devices that received FDA clearance through 2023, with 254 (36.8%) cleared in or after 2021. Device summaries often failed to report study designs (323 [46.7%]), training sample size (368 [53.3%]), and/or demographic information (660 [95.5%]). Only 6 devices (1.6%) reported data from randomized clinical trials and 53 (7.7%) from prospective studies. Few premarket summaries contained data published in peer-reviewed journals (272 [39.4%]) or provided statistical or clinical performance, including sensitivity (166 [24.0%]), specificity (152 [22.0%]), and/or patient outcomes (3 [&lt;1%]). Some devices reported safety assessments (195 [28.2%]), adherence to international safety standards (344 [49.8%]), and/or risks to health (42 [6.1%]). In all, 489 adverse events were reported involving 36 (5.2%) devices, including 458 malfunctions, 30 injuries, and 1 death. A total of 40 devices (5.8%) were recalled 113 times, primarily due to software issues.</p></sec><sec id="ab-aoi250070-9"><title>Conclusions and Relevance</title><p>This cross-sectional study suggests that despite increasing clearance of AI/ML devices, standardized efficacy, safety, and risk assessment by the FDA are lacking. Dedicated regulatory pathways and postmarket surveillance of AI/ML safety events may address these challenges.</p></sec></abstract><abstract abstract-type="teaser" specific-use="electronic"><p>This cross-sectional study assesses pre- and postmarket reporting of efficacy, safety, and risk for artificial intelligence&#8722;/machine learning&#8722;enabled medical devices cleared by the US Food and Drug Administration.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="H1-1-AOI250070"><title>Introduction</title><p>Medical devices enabled by artificial intelligence (AI) and machine learning (ML) are increasingly available for diagnosis and management in clinical areas including cancer, cardiology, and neurology.<sup><xref rid="aoi250070r1" ref-type="bibr">1</xref>,<xref rid="aoi250070r2" ref-type="bibr">2</xref></sup> Both the US Food and Drug Administration (FDA) and European Union (EU) grant authorization or European Conformity marks, respectively, to allow marketing of medical devices,<sup><xref rid="aoi250070r3" ref-type="bibr">3</xref></sup> including AI/ML devices.<sup><xref rid="aoi250070r4" ref-type="bibr">4</xref></sup> As of August 7, 2024, a total of 950 AI/ML devices have been granted clearance or approval by the FDA for clinical use, with 108 and 107 cleared in 2023 and 2024, respectively.<sup><xref rid="aoi250070r5" ref-type="bibr">5</xref></sup></p><p>The FDA and EU classify medical devices, including AI/ML devices, according to risk.<sup><xref rid="aoi250070r6" ref-type="bibr">6</xref></sup> In the US, the FDA uses 3 clearance pathways for devices. (1) De novo premarket review is intended for new low- to moderate-risk (classes I or II) devices not previously classified. (2) The 510(k) clearance is intended for devices demonstrating substantial equivalence to a legally marketed predicate device.<sup><xref rid="aoi250070r7" ref-type="bibr">7</xref></sup> However, the 510(k) process has limitations because it does not require independent clinical evidence for every new device, relying instead on comparisons to predicate devices, which may themselves have been cleared without rigorous clinical testing, potentially allowing incremental risks to accumulate over generations of devices.<sup><xref rid="aoi250070r7" ref-type="bibr">7</xref></sup> (3) The Premarket Approval (PMA) pathway is the most stringent and is typically required for devices posing a substantial risk of injury or illness (class III). Most AI/ML devices are designated class II (moderate) risk and are regulated through the 510(k) pathway, which has fewer safety reporting and postmarket surveillance requirements than the PMA pathway.<sup><xref rid="aoi250070r7" ref-type="bibr">7</xref>,<xref rid="aoi250070r8" ref-type="bibr">8</xref></sup> Additionally, one-third of AI/ML devices cleared through the 510(k) pathway originate from non-AI/ML devices.<sup><xref rid="aoi250070r9" ref-type="bibr">9</xref></sup></p><p>Unlike standards for pharmaceutical agents, there do not exist predefined standards for efficacy, safety, and risk reporting of AI/ML devices prior to or after clearance or certification.<sup><xref rid="aoi250070r7" ref-type="bibr">7</xref></sup> In particular, the FDA and EU have recognized safety and risk assessment as important regulatory priorities for AI/ML.<sup><xref rid="aoi250070r10" ref-type="bibr">10</xref>,<xref rid="aoi250070r11" ref-type="bibr">11</xref></sup> In January 2025, the US White House issued an executive order to repeal AI policies seen as barriers to innovation, particularly a prior executive order that introduced transparency requirements for AI/ML companies, although there were no immediate impacts on AI/ML medical devices.<sup><xref rid="aoi250070r12" ref-type="bibr">12</xref></sup> By contrast, the EU Parliament passed the Artificial Intelligence Act<sup><xref rid="aoi250070r10" ref-type="bibr">10</xref></sup> in March 2024 that included safety requirements that companies must meet for AI/ML models.</p><p>To our knowledge, there has not yet been a comprehensive analysis of both pre- and postmarket benefit-risk reporting for AI/ML devices cleared by the FDA as of July 2023. Through analyzing FDA decision summaries, device labels, adverse events, and recalls, we aimed to describe benefit-risk reports, including efficacy, safety, and bias assessments, submitted by manufacturers to the FDA and to analyze postmarket surveillance of adverse events and recalls.</p></sec><sec id="H1-2-AOI250070"><title>Methods</title><p>The University of Pennsylvania Institutional Review Board determined that this study was exempt from review due to it being nonhuman subjects research; informed consent was likewise waived. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.equator-network.org/reporting-guidelines/strobe/" ext-link-type="uri">STROBE</ext-link>) reporting guideline.</p><sec id="H2-1-AOI250070"><title>Data Collection and Selection Criteria</title><p>We used a publicly available FDA website to identify all AI/ML devices cleared by the FDA between September 29, 1995, and July 27, 2023.<sup><xref rid="aoi250070r5" ref-type="bibr">5</xref></sup> The website regularly updates lists of AI/ML-enabled clearances that meet the FDA definition of medical device, including SaMD (software as a medical device) and relevant clinical decision-making software. Devices were determined to incorporate AI/ML based on information provided in market authorization summaries. We linked this FDA list to the FDA 510(k), De Novo, and PMA databases between July 2023 and January 2024, obtaining decision summaries that present the scientific evidence that served as the basis for the regulatory decision as well as data on clearance dates, reviewer specialty, company, risk classification, and clearance pathway.<sup><xref rid="aoi250070r13" ref-type="bibr">13</xref></sup> We also linked devices to adverse events and device recalls using device identification codes, including 510(k), De Novo, and PMA numbers, through the FDA Manufacturer and User Facility Device Experience (MAUDE) database and the Medical Device Recalls database on November 3, 2024.<sup><xref rid="aoi250070r14" ref-type="bibr">14</xref>,<xref rid="aoi250070r15" ref-type="bibr">15</xref></sup></p></sec><sec id="H2-2-AOI250070"><title>Data Abstraction</title><p>Three investigators (J.C.L., B.J., and R.B.P.) developed a codebook for device summaries encompassing data on study design, efficacy, data availability, safety reporting, and bias assessment. Six members of the research team (J.C.L., B.J., I.R., C.K., A.R.S., and H.P.) extracted data from device summaries from July 2023 to January 2024. We also analyzed the published evidence base, adverse events, and recalls for FDA-cleared devices. Disagreements were mediated by discussion between all investigators and the principal investigator (R.B.P.) at regular meetings.</p><sec id="H3-1-AOI250070"><title>Premarket Variables</title><p>To evaluate study design and efficacy, we classified whether retrospective or prospective data were cited in summary documents and classified the study design for data reporting as comparative, cross-sectional, case-control, cohort, software validation and verification, or randomized clinical trial (definitions are available in eTable 1 in <xref rid="note-AOI250070-1-s" ref-type="supplementary-material">Supplement 1</xref>).<sup><xref rid="aoi250070r16" ref-type="bibr">16</xref>,<xref rid="aoi250070r17" ref-type="bibr">17</xref></sup> We identified whether decision documents mentioned statistical and clinical metrics of efficacy. Statistical metrics included positive predictive value, negative predictive value, sensitivity, specificity, area under the curve (AUC), accuracy, and calibration. Clinical metrics included patient outcomes (eg, survival), efficiency (eg, time to intervention), and cost (eg, cost-benefit analysis).</p><p>To assess data availability, we reviewed decision summaries to identify whether primary data supporting clearance were made available online. To evaluate the availability of related peer-reviewed publications, we searched MEDLINE and Web of Science using unique device names, manufacturer names, and/or institutions noted for each device. As many as 3 searches were attempted for each device. Investigators evaluated whether publications pertained to the AI/ML device and analyzed its performance.</p><p>To assess safety reporting, we ascertained from decision summaries whether manufacturers reported devices adhering to internationally recognized safety standards for electrical technologies (ie, American National Standards Institute [ANSI], International Electrotechnical Commission [IEC], Association for the Advancement of Medical Instrumentation [AAMI], National Electrical Manufacturers Association [NEMA], or International Organization for Standardization [ISO]).<sup><xref rid="aoi250070r13" ref-type="bibr">13</xref></sup> Then, standards organizations were classified as electrical/software, medical, or general based on areas of specialty. For health and safety risks, we searched decision summaries for any listed error or harm associated with the device, including algorithm errors, user errors, physical harm, and/or additional adverse outcomes.</p></sec><sec id="H3-2-AOI250070"><title>Postmarket Variables</title><p>To assess bias and fairness reporting, we reviewed decision summaries to evaluate whether bias assessments were conducted, specifically whether performance was reported separately for subgroups defined by race and/or ethnicity, gender or sex, age, or other factors. We also analyzed the number of reported adverse events using MAUDE and classified the reason(s) for recalls using the Medical Device Recalls database as software and hardware issues, physical and patient-related harms, or other device malfunctions.</p></sec></sec><sec id="H2-3-AOI250070"><title>Statistical Analysis</title><p>First, we summarized frequencies of relevant outcomes. Given the FDA 2021 recommendations for improving transparency and safety and bias monitoring, we compared characteristics of AI/ML devices cleared before and after 2021 to identify temporal trends using &#967;<sup>2</sup> tests; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.05 were considered statistically significant. Data analysis was performed from October to November 2024, using Stata, version 18.0 (StataCorp). Our analytic dataset is available online (<xref rid="note-AOI250070-1-s" ref-type="supplementary-material">Supplement 3</xref>).</p></sec></sec><sec id="H1-3-AOI250070"><title>Results</title><p>We identified 691 medical devices cleared and listed as AI/ML devices by the FDA (<xref rid="note-AOI250070-1-s" ref-type="supplementary-material">Supplement 2</xref>). Characteristics of the included devices are described in <xref rid="aoi250070t1" ref-type="table">Table 1</xref>. Devices were classified by the FDA as risk class II (moderate to high risk; 691 [100%]) and were cleared through the 510(k) (668 [96.7%]), De Novo (n&#8201;=&#8201;20 [2.9%]), or PMA (n&#8201;=&#8201;3 [&lt;1%]) pathways.</p><table-wrap position="float" id="aoi250070t1" orientation="portrait"><label>Table 1. </label><caption><title>Characteristics of Artificial Intelligence/Machine Learning&#8722;Enabled Medical Devices Cleared by the US Food and Drug Administration, 1995 to 2023</title></caption><table frame="hsides" rules="groups"><col width="72.84%" span="1"/><col width="27.16%" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Characteristic</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Devices, No. (%)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Device and clearance</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Risk class II</td><td valign="top" align="left" rowspan="1" colspan="1">691 (100)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Clearance pathway</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 510(k)</td><td valign="top" align="left" rowspan="1" colspan="1">668 (96.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> De Novo</td><td valign="top" align="left" rowspan="1" colspan="1">20 (2.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> PMA</td><td valign="top" align="left" rowspan="1" colspan="1">3 (0.4)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Clearance time</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 1995-2021</td><td valign="top" align="left" rowspan="1" colspan="1">437 (63.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2021-Present</td><td valign="top" align="left" rowspan="1" colspan="1">254 (36.8)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Specialty panel</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Radiology</td><td valign="top" align="left" rowspan="1" colspan="1">531 (76.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Cardiovascular medicine</td><td valign="top" align="left" rowspan="1" colspan="1">70 (10.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Neurology</td><td valign="top" align="left" rowspan="1" colspan="1">20 (2.9)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hematology</td><td valign="top" align="left" rowspan="1" colspan="1">15 (2.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Gastroenterology-urology</td><td valign="top" align="left" rowspan="1" colspan="1">11 (1.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other</td><td valign="top" align="left" rowspan="1" colspan="1">44 (6.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Study components reported</td><td valign="top" align="left" rowspan="1" colspan="1">368 (53.3)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Study type</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Comparative</td><td valign="top" align="left" rowspan="1" colspan="1">149 (40.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Cross sectional</td><td valign="top" align="left" rowspan="1" colspan="1">95 (25.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Case-control</td><td valign="top" align="left" rowspan="1" colspan="1">63 (17.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Cohort</td><td valign="top" align="left" rowspan="1" colspan="1">55 (15.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Randomized clinical trial</td><td valign="top" align="left" rowspan="1" colspan="1">6 (1.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Data collection method</td><td valign="top" align="left" rowspan="1" colspan="1">305 (44.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Retrospective</td><td valign="top" align="left" rowspan="1" colspan="1">252 (82.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Prospective</td><td valign="top" align="left" rowspan="1" colspan="1">49 (16.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Both</td><td valign="top" align="left" rowspan="1" colspan="1">4 (1.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Site location(s)</td><td valign="top" align="left" rowspan="1" colspan="1">127 (18.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Median (IQR)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (2-7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Sample size</td><td valign="top" align="left" rowspan="1" colspan="1">323 (46.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Median (IQR)</td><td valign="top" align="left" rowspan="1" colspan="1">300 (135-700)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Demographic characteristics</td><td valign="top" align="left" rowspan="1" colspan="1">31 (4.5)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Participants of racial or ethnic minority group </td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &lt;20%</td><td valign="top" align="left" rowspan="1" colspan="1">13 (42.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 20%-50%</td><td valign="top" align="left" rowspan="1" colspan="1">9 (29.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &gt;50%</td><td valign="top" align="left" rowspan="1" colspan="1">9 (29.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Bias assessment</td><td valign="top" align="left" rowspan="1" colspan="1">60 (8.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Sex</td><td valign="top" align="left" rowspan="1" colspan="1">49 (81.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Age</td><td valign="top" align="left" rowspan="1" colspan="1">37 (61.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Race and ethnicity</td><td valign="top" align="left" rowspan="1" colspan="1">17 (28.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Body mass index</td><td valign="top" align="left" rowspan="1" colspan="1">5 (8.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Diabetes</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Skin tone</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Publicly available testing or validation</td><td valign="top" align="left" rowspan="1" colspan="1">79 (11.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Associated with peer-reviewed research</td><td valign="top" align="left" rowspan="1" colspan="1">272 (39.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 1-2</td><td valign="top" align="left" rowspan="1" colspan="1">160 (58.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 3-9</td><td valign="top" align="left" rowspan="1" colspan="1">88 (32.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &#8805;10</td><td valign="top" align="left" rowspan="1" colspan="1">24 (8.8)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Postmarket approval</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Adverse events reported</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Yes</td><td valign="top" align="left" rowspan="1" colspan="1">36 (5.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No</td><td valign="top" align="left" rowspan="1" colspan="1">655 (94.8)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Recall(s)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Yes</td><td valign="top" align="left" rowspan="1" colspan="1">40 (5.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No</td><td valign="top" align="left" rowspan="1" colspan="1">651 (94.2)</td></tr></tbody></table><table-wrap-foot><p>Abbreviation: PMA, Premarket Approval pathway.</p></table-wrap-foot></table-wrap><p>The medical devices analyzed were classified under 17 unique medical specialty panels. Of these specialties, radiology comprised the most devices (n&#8201;=&#8201;531 [76.9%]), followed by cardiovascular medicine (n&#8201;=&#8201;70 [10.1%]), neurology (n&#8201;=&#8201;20 [2.9%]), hematology (n&#8201;=&#8201;15 [2.2%]), and gastroenterology-urology (n&#8201;=&#8201;11 [1.6%]).</p><sec id="H2-4-AOI250070"><title>Reporting of Study Design, Data Availability, and Efficacy</title><p>In total, 323 device summaries (46.7%) did not report study design. For the 368 devices (53.3%) that reported study design (eFigure 1 in <xref rid="note-AOI250070-1-s" ref-type="supplementary-material">Supplement 1</xref>), the most common design was comparative (n&#8201;=&#8201;149 [40.5%]), followed by cross-sectional (n&#8201;=&#8201;95 [25.8%]), case-control (n&#8201;=&#8201;63 [17.1%]), cohort (n&#8201;=&#8201;55 [15.0%]), and randomized clinical trial (n&#8201;=&#8201;6 [1.6%]).</p><p>Most device summaries did not report timing of data collection (n&#8201;=&#8201;386 [55.9%]), number of site locations (n&#8201;=&#8201;564 [81.6%]), or sample sizes (n&#8201;=&#8201;368 [53.3%]). Among 305 devices (44.1%) that reported timing of data collection, the most common was retrospective (n&#8201;=&#8201;252 [82.6%]), followed by prospective (n&#8201;=&#8201;49 [16.1%]) or both (n&#8201;=&#8201;4 [1.3%]) (eFigure 2 in <xref rid="note-AOI250070-1-s" ref-type="supplementary-material">Supplement 1</xref>). There was little variability in the number of site locations included in AI/ML device assessments (median [IQR], 4 [2-7]). The median (IQR) sample size was 300 (135-700), although this ranged from 5 to 374&#8201;160 participants. Of the 31 devices (4.5%) that reported the demographic characteristics, the study population of 13 devices (41.9%) comprised less than 20% participants of racial or ethnic minority groups; 9 (29.0%) between 20% and 50%; and 9 (29.0%) more than 50%.</p><p>Most devices (612 [88.6%]) did not make data from testing or validation available online and were not associated with a peer-reviewed research publication (419 [60.6%]). Among the 272 devices (39.4%) associated with peer-reviewed research, 160 (58.8%) were associated with 1 or 2 publications, while 24 (8.8%) were associated with 10 or more publications.</p><p>Few device summaries provided most statistical or clinical outcomes, including sensitivity (166 [24.0%]), specificity (152 [22.0%]), positive predictive value (PPV; 43 [6.2%]), negative predictive value (NPV; 36 [5.2%]), AUC (43 [6.2%]), or accuracy (33 [4.8%]). Few reported efficiency (5 [&lt;1%]) or patient outcomes, such as vital signs and overall survival (n&#8201;=&#8201;3 [&lt;1%]).</p></sec><sec id="H2-5-AOI250070"><title>Reporting of Safety, Risks, and Adverse Events</title><p>Manufacturers did not report the results of a safety assessment for 496 devices (71.8%) or bias assessment for 631 devices (91.3%) and did not report adherence to international safety standards for 347 devices (50.2%) (<xref rid="aoi250070f1" ref-type="fig">Figure</xref>). Examples of safety assessments are described in <xref rid="aoi250070t2" ref-type="table">Table 2</xref>. For devices reporting compliance with safety standards, the most common standards were electrical or software (300 [43.4%]) followed by medical (182 [26.3%]). Common standards organizations included IEC (293 [42.4%]), ISO (252 [36.5%]), NEMA (153 [22.1%]), and ANSI (123 [17.8%]). Only 42 (6.1%) devices reported potential risks to health (<xref rid="aoi250070t3" ref-type="table">Table 3</xref>), such as physical harm (17 [2.5%]), algorithmic errors (29 [4.2%]), and user errors (30 [4.3%]). There was an association between approval pathway (510[k], De Novo, PMA) and reporting of safety assessments (510[k], 486 of 668 [72.8%]; De Novo, 9 of 20 [45.0%]; and PM, 1 of 3 [33.3%]; <italic toggle="yes">P</italic>&#8201;=&#8201;.008), but not reporting of bias assessments or adverse events. In total, 489 adverse events were reported to the FDA for 36 devices (5.2%) , including 458 malfunctions, 30 injuries, and 1 death.</p><fig position="float" id="aoi250070f1" fig-type="figure" orientation="portrait"><label>Figure. </label><caption><title>Safety Standards Reported by US Food and Drug Administration Approved Artificial Intelligence/Machine Learning&#8722;Enabled Medical Devices</title><p>ANSI indicates American National Standards Institute; IEC, International Electrotechnical Commission; NEMA, National Electrical Manufacturers Association; ISO, International Organization for Standardization.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jamahealthforum-e253351-g001.jpg"/></fig><table-wrap position="float" id="aoi250070t2" orientation="portrait"><label>Table 2. </label><caption><title>Selected Summaries of Safety Assessments Performed for Artificial Intelligence/Machine Learning&#8722;Enabled Medical Devices<xref rid="aoi250070t2n1" ref-type="table-fn"><sup>a</sup></xref></title></caption><table frame="hsides" rules="groups"><col width="21.35%" span="1"/><col width="19.16%" span="1"/><col width="59.49%" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Device name</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Manufacturer</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Description of safety</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">THINQ</td><td valign="top" align="left" rowspan="1" colspan="1">CorticoMetrics</td><td valign="top" align="left" rowspan="1" colspan="1">Validation included performance testing for accuracy (comparisons to expert-labeled brain images) and reproducibility (test-retest image data).</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">BodyGuardian Remote Monitoring System</td><td valign="top" align="left" rowspan="1" colspan="1">Preventice Technologies</td><td valign="top" align="left" rowspan="1" colspan="1">EMC and electrical safety testing, software verification/validation, biocompatibility for patient contact materials, performance testing, predicate device comparison tests, usability testing.</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Biograph Vision, Biograph mCT family of PET/CTs</td><td valign="top" align="left" rowspan="1" colspan="1">Siemens Medical Solutions</td><td valign="top" align="left" rowspan="1" colspan="1">All features (resolution, count rate/scatter/sensitivity, image quality, coregistration accuracy) tested during verification/validation testing and met the predetermined acceptance criteria. Changes (OncoFreeze AI [data-driven gating], SUVmax, SUVmean, volume measurement) underwent scientific evaluation.</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hepatic VCAR</td><td valign="top" align="left" rowspan="1" colspan="1">GE Medical Systems</td><td valign="top" align="left" rowspan="1" colspan="1">Quality assurance measures have been applied to the development of the device: risk analysis, requirements reviews, design reviews, performance testing (verification, validation), safety testing (verification).</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Accelerate Pheno System, PhenoTest BC kit</td><td valign="top" align="left" rowspan="1" colspan="1">Accelerate Diagnostics</td><td valign="top" align="left" rowspan="1" colspan="1">Performance established during an internal performance evaluation study, with results. Internal reproducibility study conducted according to FDA AST class II Special Controls guidance, with results. Electrical safety and EMC testing is identical to that conducted for the predicate device. Software verification and validation testing conducted and documentation provided.</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: AI, artificial intelligence; AST, antimicrobial susceptibility test; BC, blood culture; EMC, electromagnetic compatibility; FDA, US Food and Drug Administration; PET/CT, positron emission tomography/computed tomography; SUV, standard uptake value; VCAR, volume computer assisted reading.</p><fn id="aoi250070t2n1"><label>
<sup>a</sup>
</label><p>These excerpts and the complete descriptions of safety assessments are available from FDA (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm" ext-link-type="uri">accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm</ext-link>).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="aoi250070t3" orientation="portrait"><label>Table 3. </label><caption><title>Safety Risks of Artificial Intelligence/Machine Learning&#8722;Enabled Medical Devices Reported in Decision Summaries</title></caption><table frame="hsides" rules="groups"><col width="21.85%" span="1"/><col width="10.91%" span="1"/><col width="67.24%" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Safety risk</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Devices, No.</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Examples</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Algorithm errors</td><td valign="top" align="left" rowspan="1" colspan="1">29</td><td valign="top" align="left" rowspan="1" colspan="1">Device failure or delay, data corruption, false positives/negatives</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">User errors</td><td valign="top" align="left" rowspan="1" colspan="1">30</td><td valign="top" align="left" rowspan="1" colspan="1">Improper dosing, device misuse, misinterpretation of results</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Physical harm</td><td valign="top" align="left" rowspan="1" colspan="1">17</td><td valign="top" align="left" rowspan="1" colspan="1">Adverse tissue reaction, electrical shock, eye hazard or injury</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Other risks</td><td valign="top" align="left" rowspan="1" colspan="1">3</td><td valign="top" align="left" rowspan="1" colspan="1">Data breaches due to insecure transmission of data, interference with other devices</td></tr></tbody></table></table-wrap></sec><sec id="H2-6-AOI250070"><title>Device Recalls</title><p>Forty devices (5.8%) were recalled 113 times in total for reasons including software or hardware issues, physical harm to patients, or other device malfunctions (<xref rid="aoi250070t4" ref-type="table">Table 4</xref>). Most recalls (85 [75.2%]) were due to software issues, such as delays in starting hardware and patient management, improper dosing of medications, and imaging scans being lost or sent to multiple patients. Some (26 [23.0%]) recalls were due to physical- or patient-related harms (eg, excessive noise that could cause hearing loss). Devices with adverse events were more likely to be recalled than those without adverse events (14 of 36 [38.9%] vs 26 of 655 [4.0%]; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001).</p><table-wrap position="float" id="aoi250070t4" orientation="portrait"><label>Table 4. </label><caption><title>Characteristics of Recalls of Artificial Intelligence/Machine Learning&#8722;Enabled Medical Devices</title></caption><table frame="hsides" rules="groups"><col width="10.66%" span="1"/><col width="7.02%" span="1"/><col width="16.68%" span="1"/><col width="8.34%" span="1"/><col width="57.3%" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Device name</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Recalls, No.</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Reason for recall</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Patient harm</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Example of recall details</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">A</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Device failure</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Low battery life</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">B</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Device failure</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Internal failure of the vertical/horizontal tilt adjustment mechanism</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">C</td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1">Device failure</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Improperly formulated and released fluorescence in situ hybridization probes resulting in false positives</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">D</td><td valign="top" align="left" rowspan="1" colspan="1">10</td><td valign="top" align="left" rowspan="1" colspan="1">Software and device failure</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Complaints due to compromised hyperbaric chamber, optical degradation may potentially cause a delay in reporting results</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">E</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Device failure</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Issue with locking mechanism preventing scanning</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">F</td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1">Device failure</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Issue with locking mechanism preventing scanning</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">G</td><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1">Physical harm, software and device failure</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Elevated acoustic noise during scanning, potentially leading to hearing loss</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">H</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Device failure</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Lubricating grease may cause visible, dot- or line-shaped, fat-isointense artifacts during head examinations</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">I</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Device failure</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Lubricating grease may cause visible, dot- or line-shaped, fat-isointense artifacts during head examinations</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">J</td><td valign="top" align="left" rowspan="1" colspan="1">27</td><td valign="top" align="left" rowspan="1" colspan="1">Software and device failure</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Issue with propagation of treatment course information, software error resulting in local underestimation of expected dose, issues applying pitch/roll correction</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">K</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Device failure</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Initial delivery positions will be set incorrectly despite calibration</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">L</td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1">Device failure</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">System operator is able to bypass the SmokeDetector Interlock system locking mechanism after a smoke detection</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">M</td><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1">Software and device failure</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Potential for Incorrect Image Orientation resulting images may be flipped or reversed result in misdiagnosis, incorrect treatment of a condition, or additional radiation exposure if a rescan is required</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">N</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">Software and device failure</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Dosing errors and duplication, software issues resulting in incorrect data transmission and patient care planning</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">O</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Device failure</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Probe handle may crack</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">P</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Device failure</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Potential for amplified noise and/or overall signal reduction, which may interfere with intended recordings of heart rhythms</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Q</td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1">Software and labeling</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Default reference ranges are incorrectly displayed, resulting in incorrect readings</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">R</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Labeling</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Missing precautionary statements</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">S</td><td valign="top" align="left" rowspan="1" colspan="1">7</td><td valign="top" align="left" rowspan="1" colspan="1">Physical harm and software</td><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="left" rowspan="1" colspan="1">Potential for composed images to be flipped, resulting in misdiagnosis</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">T</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Software</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Low sensitivity, resulting in delays in diagnosis and treatment</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">U</td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1">Software</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Wrong calculation of the dose/min for fluoroscopy examinations</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">V</td><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">Software</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">May bring up another patient when comparing scans</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">W</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Software</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Insufficient documentation of quality procedures</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">X</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Software</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Data transmission issues</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Y</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Software</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Inability to boot up in timely fashion</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Z</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Software</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Inability to boot up in timely fashion</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">AA</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Software</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Duplicate logging of a blood glucose level reading</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">AB</td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1">Software</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Inconsistent configuration</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">AC</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Software</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Data not properly transmitted</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">AD</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Software</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Partial electrical reset results in inability to detect and report Brady and Pause events</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">AE</td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1">Software</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Incorrect dosing or dose applied to the wrong location</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">AF</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Software</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Incorrect measurements</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">AG</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Software</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">CT scan failing resulting in rescanning and reinjection of contrast medium.</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">AH</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Software</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Unintended video frames being included, resulting in incorrect estimates</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">AI</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Software</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Diagnostic imaging system failing resulting in rescanning and reinjection of contrast medium</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">AJ</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Software</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Potential for data loss</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">AK</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Software</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Potential interruption of data communication</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">AL</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Software</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Issues with terminating scan, resulting in treatment delay</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">AM</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">Software</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">Misleading and out-of-sync display</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">AN</td><td valign="top" align="left" rowspan="1" colspan="1">2</td><td valign="top" align="left" rowspan="1" colspan="1">Software and device failure</td><td valign="top" align="left" rowspan="1" colspan="1">No</td><td valign="top" align="left" rowspan="1" colspan="1">False-negative results due to reagent packs exhibiting low signal</td></tr></tbody></table><table-wrap-foot><p>Abbreviation: CT, computed tomography.</p></table-wrap-foot></table-wrap></sec><sec id="H2-7-AOI250070"><title>Temporal Trends</title><p>Relative to FDA devices cleared before 2021, devices cleared during or after 2021 were more likely to publish data online (72 of 254 [28.4%] vs 7 of 437 [1.6%]; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001); evaluate demographic bias (49 of 254 [19.3%] vs 11 of 437 [2.5%]; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001); and report study timing (133 of 254 [52.4%] vs 172 of 437 [39.4%]; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001), efficacy (91 of 254 [35.8%] vs 104 of 437 [23.8%]; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001) and clinical (28 of 254 [11.0%] vs 5 of 437 [1.1%]; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001) outcomes. However, devices approved during or after 2021 were less likely to be associated with a peer-reviewed publication (81 of 254 [31.9%] vs 191 of 437 [43.7%]; <italic toggle="yes">P</italic>&#8201;=&#8201;.002), report safety assessment results (34 of 254 [13.4%] vs 161 of 437 [36.8%]; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001), and have adverse events (5 of 254 [2.0%] vs 31 of 437 [7.1%]; <italic toggle="yes">P</italic>&#8201;=&#8201;.003) than those approved before 2021. No differences were identified in reported study design (observational vs controlled), study timing (prospective vs retrospective), adherence to international standards, reporting of health risks, or recalls (eTable 2 in <xref rid="note-AOI250070-1-s" ref-type="supplementary-material">Supplement 1</xref>). Devices cleared through the 510(k) pathway before 2021 were marginally more likely to report safety and bias assessments. However, this relationship was not evident for devices approved through the same pathway during or after 2021 (eTable 2 in <xref rid="note-AOI250070-1-s" ref-type="supplementary-material">Supplement 1</xref>).</p></sec></sec><sec id="H1-4-AOI250070"><title>Discussion</title><p>In this cross-sectional study of all FDA-cleared AI/ML devices from September 1995 to July 2023, a large proportion of decision summaries&#8212;intended to contain data supporting clearance&#8212;lacked information regarding study design, timing, efficacy, clinical outcomes, safety assessment, adherence to safety standards, demographic characteristics, bias assessment, and data availability. Most cleared devices did not have a study design or timing included in the clearance summary or in a peer-reviewed publication. Additionally, for the few devices that did report study design and timing, most were cleared based on retrospective observational studies. Some devices (39.4%) had results that were published in peer-reviewed literature. Safety risks reporting was uncommon (6.1%), usually focused on algorithmic or user errors, and did not adhere to international safety standards (ie, IEC, ISO, NEMA, or ANSI).</p><p>Our findings were consistent with previous evidence<sup><xref rid="aoi250070r7" ref-type="bibr">7</xref>,<xref rid="aoi250070r8" ref-type="bibr">8</xref></sup> in an older cohort of approvals, suggesting a paucity of prospective evidence for AI/ML devices. Our study augments these findings by elucidating pre- and postmarket safety concerns, including finding that 5.2% of devices reported postmarket adverse events and 5.8% of cleared devices were recalled, with a meaningful percentage of recalls due to patient-specific harms. These rates are lower than the rates of adverse events and recalls of non-AI/ML devices submitted in the 510(k) pathway,<sup><xref rid="aoi250070r18" ref-type="bibr">18</xref>,<xref rid="aoi250070r19" ref-type="bibr">19</xref></sup> such as surgical and implantable devices.<sup><xref rid="aoi250070r20" ref-type="bibr">20</xref>,<xref rid="aoi250070r21" ref-type="bibr">21</xref>,<xref rid="aoi250070r22" ref-type="bibr">22</xref>,<xref rid="aoi250070r23" ref-type="bibr">23</xref></sup> However, this finding raises concerns about the adequacy of the 510(k) framework for evaluating substantial equivalence for medical devices, particularly AI/ML devices, as the absence of robust clinical validation may limit the ability to assess performance and patient impact in the community setting.<sup><xref rid="aoi250070r18" ref-type="bibr">18</xref>,<xref rid="aoi250070r19" ref-type="bibr">19</xref></sup> Existing FDA postmarket surveillance databases documented 489 adverse events for 36 devices and 111 recalls of 39 devices; devices with adverse events were more likely to be recalled.</p><p>Radiology and cardiovascular medicine were the most common specialties for devices. Medical device applications are designated to 1 of 19 FDA specialty panels for review; each has varying levels of workload and resources.<sup><xref rid="aoi250070r24" ref-type="bibr">24</xref></sup> Moreover, reporting of safety results and risks to health, as well as adherence to international standards, did not improve after 2021. These findings suggest that premarket safety information for AI/ML devices may be insufficient and more robust postmarket surveillance systems are necessary to capture health-related adverse events and safety concerns relevant to AI/ML devices. In particular, known degradation in performance of AI/ML algorithms complicates traditional surveillance methods.<sup><xref rid="aoi250070r25" ref-type="bibr">25</xref></sup> Nonlocked AI/ML models can self-learn based on new data acquired during patient care, but AI/ML algorithm performance often drifts over time.<sup><xref rid="aoi250070r26" ref-type="bibr">26</xref>,<xref rid="aoi250070r27" ref-type="bibr">27</xref></sup> Voluntary adverse event reporting databases, such as MAUDE, may not capture eventual diagnostic or prognostic errors associated with these AI/ML performance gaps. It may be critical to establish consensus on what constitutes an AI/ML-related adverse event to implement dedicated automated mechanisms for postmarket surveillance of AI/ML devices, potentially through linkages to EHR systems.</p><p>Moreover, we find that most risks to health reported in existing surveillance systems focus on algorithmic and user errors, neglecting the need for standardized characterization of patient-level safety risks associated with AI/ML devices. These could include standardized adverse events (eg, unnecessary biopsies, missed diagnoses of pathologic specimens) that could result from faulty AI/ML devices. Furthermore, the well-documented underreporting of safety events in MAUDE necessitates a shift toward more proactive safety monitoring.<sup><xref rid="aoi250070r28" ref-type="bibr">28</xref></sup> Leveraging end user health systems to report safety events and performance drift of FDA-cleared devices could provide a more comprehensive and timely understanding of how AI may affect patient outcomes. In 2021, the FDA called for improving transparency, monitoring safety and bias, and ensuring test-data quality of AI/ML devices.<sup><xref rid="aoi250070r7" ref-type="bibr">7</xref></sup> We found that even when bias and safety were evaluated, results were typically not disclosed to the public.</p><p>AI/ML devices cleared after 2021 were mostly reliant on retrospective observational studies.<sup><xref rid="aoi250070r7" ref-type="bibr">7</xref></sup> These findings add to prior evidence noting overwhelmingly nonprospective data underlying AI/ML device clearances. Our study adds to prior literature by characterizing temporal trends in evidence quality for AI/ML devices. There were some improvements over time in transparency: post-2021 devices were substantially more likely to report study timing (52.4% post-2021 vs 39.4% pre-2021), efficacy (35.8% vs 23.8%), and clinical outcomes (11.0% vs 1.1%). Based on its pathway, devices cleared before 2021 varied in their reporting of safety and bias assessments&#8212;this association was not observed in devices cleared during 2021 and after. However, devices cleared after 2021 were also less likely to be associated with peer-reviewed research. Overall, greater standardization of transparent outcome reporting is essential for premarket clearance of AI/ML devices.</p><p>Our findings also show a pressing need to center health equity in the development of AI/ML devices. Most devices did not report the study population&#8217;s demographic characteristics (95.5%) and bias assessment (91.3%) for the patients in whom their algorithms were tested. Among the few that did report demographic information, individuals of racial or ethnic minority groups were underrepresented. This imbalance was further exacerbated by the limited scope of bias assessments conducted, which primarily focus on sex and age. Critical factors such as race and ethnicity, body mass index, and skin tone were often not reported. Lacking these comprehensive evaluations can lead to AI/ML devices inadvertently embedding and amplifying existing biases in clinical care.<sup><xref rid="aoi250070r29" ref-type="bibr">29</xref></sup> Although reporting of bias calculations improved after 2020, in public reports and documents 80.7% of devices still lacked relevant demographic information about their training or testing cohort.</p><sec id="H2-8-AOI250070"><title>Limitations</title><p>Our study has several limitations worth noting. First, while decision summaries aim to provide a comprehensive overview of scientific data, they may not always contain all necessary information submitted to the FDA for clinical use.<sup><xref rid="aoi250070r13" ref-type="bibr">13</xref></sup> However, most efficacy and safety data are expected to be included in these summaries and should promote public transparency. Second, additional safety assessments may occur after FDA clearance, meaning the full scope of information essential for clinical use may not always be available in premarket decision summaries. However, we extensively interrogated adverse event and recall databases to capture potential safety issues attributable to these devices. Third, devices may receive multiple FDA clearances over time, and our analysis was conducted at the level of individual clearances, which may not capture all prior or subsequent regulatory decisions. In addition, certain data, such as the number of peer-reviewed publications, can be challenging to link to specific devices due to differences between the submitted and published versions of a device name or type. To attempt to address this, we conducted at least 2 independent reviews of each publication to verify its relationship with each device.</p><p>Several key considerations warrant further attention. First, the Instructions for Use for each device did not yield relevant information for our analysis. Second, the low number of reported adverse events raises concerns about the adequacy of postmarket surveillance. Our statistical analyses underscore the need for more robust reporting mechanisms to ensure accurate postmarket safety assessments. Lastly, our study did not differentiate between locked and generative AI in the regulatory approval process due to an inadequate sample of generative AI devices (2 of 691 [0.3%]). Future research should explore whether the clearance pathways differ between these AI types and how regulatory oversight adapts to the unique risks and challenges posed by generative AI.</p></sec></sec><sec id="H1-5-AOI250070"><title>Conclusions</title><p>This cross-sectional study found that improved premarket data transparency and rigorous evaluation of AI/ML device efficacy and safety are needed. Using decision summaries for FDA-cleared AI/ML devices linked to adverse event and recall data, we found that currently, devices lack transparent efficacy or safety evaluations despite postmarket safety events being observed. To date, the FDA does not have a dedicated regulatory pathway for AI/ML devices.<sup><xref rid="aoi250070r4" ref-type="bibr">4</xref></sup> Given the unique considerations of these devices, implementation of a dedicated regulatory system for AI/ML devices, including more rigorous standards for study design and transparency, should be considered. Additionally, a more rigorous postmarket monitoring system may facilitate trust in integrating AI/ML devices into clinical settings.</p></sec></body><back><ref-list id="REF-AOI250070"><title>References</title><ref id="aoi250070r1"><label>1</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Lopez</surname><given-names>CD</given-names></string-name>, <string-name name-style="western"><surname>Boddapati</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Lombardi</surname><given-names>JM</given-names></string-name>, <etal/></person-group>. <article-title>Artificial learning and machine learning applications in spine surgery: a systematic review</article-title>. <source>Global Spine J</source>. <year>2022</year>;<volume>12</volume>(<issue>7</issue>):<fpage>1561</fpage>-<lpage>1572</lpage>. doi:<pub-id pub-id-type="doi">10.1177/21925682211049164</pub-id><pub-id pub-id-type="pmid">35227128</pub-id><pub-id pub-id-type="pmcid">PMC9393994</pub-id></mixed-citation></ref><ref id="aoi250070r2"><label>2</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Arya</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Dias</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Jelinek</surname><given-names>HF</given-names></string-name>, <string-name name-style="western"><surname>Hadjileontiadis</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Pappa</surname><given-names>AM</given-names></string-name></person-group>. <article-title>The convergence of traditional and digital biomarkers through AI-assisted biosensing: a new era in translational diagnostics?</article-title><source>Biosens Bioelectron</source>. <year>2023</year>;<volume>235</volume>:<elocation-id>115387</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.bios.2023.115387</pub-id><pub-id pub-id-type="pmid">37229842</pub-id></mixed-citation></ref><ref id="aoi250070r3"><label>3</label><mixed-citation publication-type="book"><person-group><collab>US Institute of Medicine</collab></person-group>. <source>Medical Devices and the Public&#8217;s Health: The FDA 510(k) Clearance Process at 35 Years</source>. The National Academies Press; <year>2011</year>. doi:<pub-id pub-id-type="doi">10.17226/13150</pub-id></mixed-citation></ref><ref id="aoi250070r4"><label>4</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Muehlematter</surname><given-names>UJ</given-names></string-name>, <string-name name-style="western"><surname>Daniore</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Vokinger</surname><given-names>KN</given-names></string-name></person-group>. <article-title>Approval of artificial intelligence and machine learning-based medical devices in the USA and Europe (2015-20): a comparative analysis</article-title>. <source>Lancet Digit Health</source>. <year>2021</year>;<volume>3</volume>(<issue>3</issue>):<fpage>e195</fpage>-<lpage>e203</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2589-7500(20)30292-2</pub-id><pub-id pub-id-type="pmid">33478929</pub-id></mixed-citation></ref><ref id="aoi250070r5"><label>5</label><mixed-citation publication-type="webpage"><person-group><collab>Center for Devices and Radiological Health</collab></person-group>. Artificial intelligence and machine learning (AI/ML)-enabled medical devices. <italic toggle="yes">FDA</italic>. Published online October 5, 2022. Accessed May 3, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices" ext-link-type="uri">https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices</ext-link></mixed-citation></ref><ref id="aoi250070r6"><label>6</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Sorenson</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Drummond</surname><given-names>M</given-names></string-name></person-group>. <article-title>Improving medical device regulation: the United States and Europe in perspective</article-title>. <source>Milbank Q</source>. <year>2014</year>;<volume>92</volume>(<issue>1</issue>):<fpage>114</fpage>-<lpage>150</lpage>. doi:<pub-id pub-id-type="doi">10.1111/1468-0009.12043</pub-id><pub-id pub-id-type="pmid">24597558</pub-id><pub-id pub-id-type="pmcid">PMC3955380</pub-id></mixed-citation></ref><ref id="aoi250070r7"><label>7</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Wu</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Daneshjou</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ouyang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ho</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Zou</surname><given-names>J</given-names></string-name></person-group>. <article-title>How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals</article-title>. <source>Nat Med</source>. <year>2021</year>;<volume>27</volume>(<issue>4</issue>):<fpage>582</fpage>-<lpage>584</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41591-021-01312-x</pub-id><pub-id pub-id-type="pmid">33820998</pub-id></mixed-citation></ref><ref id="aoi250070r8"><label>8</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Joshi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Jain</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Araveeti</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Adhikari</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Garg</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Bhandari</surname><given-names>M</given-names></string-name></person-group>. <article-title>FDA-approved artificial intelligence and machine learning (AI/ML)-enabled medical devices: an updated landscape</article-title>. <source>Electronics (Basel)</source>. <year>2024</year>;<volume>13</volume>(<issue>3</issue>):<fpage>498</fpage>. doi:<pub-id pub-id-type="doi">10.3390/electronics13030498</pub-id></mixed-citation></ref><ref id="aoi250070r9"><label>9</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Muehlematter</surname><given-names>UJ</given-names></string-name>, <string-name name-style="western"><surname>Bluethgen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Vokinger</surname><given-names>KN</given-names></string-name></person-group>. <article-title>FDA-cleared artificial intelligence and machine learning-based medical devices and their 510(k) predicate networks</article-title>. <source>Lancet Digit Health</source>. <year>2023</year>;<volume>5</volume>(<issue>9</issue>):<fpage>e618</fpage>-<lpage>e626</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2589-7500(23)00126-7</pub-id><pub-id pub-id-type="pmid">37625896</pub-id></mixed-citation></ref><ref id="aoi250070r10"><label>10</label><mixed-citation publication-type="webpage"><person-group><string-name name-style="western"><surname>Bracy</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Andrews</surname><given-names>C</given-names></string-name></person-group>. EU countries vote unanimously to approve AI Act. Published February 4, <year>2024</year>. Accessed March 4, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://iapp.org/news/a/eu-countries-vote-unanimously-to-approve-ai-act/" ext-link-type="uri">https://iapp.org/news/a/eu-countries-vote-unanimously-to-approve-ai-act/</ext-link></mixed-citation></ref><ref id="aoi250070r11"><label>11</label><mixed-citation publication-type="webpage"><person-group><collab>US Food and Drug Administration, Center for Devices and Radiological Health</collab></person-group>. Artificial Intelligence and Machine Learning in Software as a Medical Device. Published online October 20, 2023. Accessed March 4, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-software-medical-device" ext-link-type="uri">https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-software-medical-device</ext-link></mixed-citation></ref><ref id="aoi250070r12"><label>12</label><mixed-citation publication-type="webpage"><person-group><collab>The White House</collab></person-group>. Executive Order 14179: Removing Barriers to American Leadership in Artificial Intelligence. The White House. Published January 23, <year>2025</year>. Accessed March 30, 2025. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.whitehouse.gov/presidential-actions/2025/01/removing-barriers-to-american-leadership-in-artificial-intelligence/" ext-link-type="uri">https://www.whitehouse.gov/presidential-actions/2025/01/removing-barriers-to-american-leadership-in-artificial-intelligence/</ext-link></mixed-citation></ref><ref id="aoi250070r13"><label>13</label><mixed-citation publication-type="webpage"><person-group><collab>US Food and Drug Administration, Center for Devices and Radiological Health</collab></person-group>. Evaluation of Automatic Class III Designation (De Novo) Summaries. Published online February 9, 2024. Accessed February 23, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/about-fda/cdrh-transparency/evaluation-automatic-class-iii-designation-de-novo-summaries" ext-link-type="uri">https://www.fda.gov/about-fda/cdrh-transparency/evaluation-automatic-class-iii-designation-de-novo-summaries</ext-link></mixed-citation></ref><ref id="aoi250070r14"><label>14</label><mixed-citation publication-type="webpage"><person-group><collab>US Food and Drug Administration</collab></person-group>. FDA Manufacturer and User Facility Device Experience. Accessed March 3, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm" ext-link-type="uri">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm</ext-link></mixed-citation></ref><ref id="aoi250070r15"><label>15</label><mixed-citation publication-type="webpage"><person-group><collab>US Food and Drug Administration, Center for Devices and Radiological Health</collab></person-group>. Medical Device Recalls. Published February 14, <year>2024</year>. Accessed March 3, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/medical-devices/medical-device-safety/medical-device-recalls" ext-link-type="uri">https://www.fda.gov/medical-devices/medical-device-safety/medical-device-recalls</ext-link></mixed-citation></ref><ref id="aoi250070r16"><label>16</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Manja</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Lakshminrusimha</surname><given-names>S</given-names></string-name></person-group>. <article-title>Epidemiology and clinical research design, part 1: study types</article-title>. <source>Neoreviews</source>. <year>2014</year>;<volume>15</volume>(<issue>12</issue>):<fpage>e558</fpage>-<lpage>e569</lpage>. doi:<pub-id pub-id-type="doi">10.1542/neo.15-12-e558</pub-id><pub-id pub-id-type="pmid">25848346</pub-id><pub-id pub-id-type="pmcid">PMC4384651</pub-id></mixed-citation></ref><ref id="aoi250070r17"><label>17</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Goldsack</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Coravos</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bakker</surname><given-names>JP</given-names></string-name>, <etal/></person-group>. <article-title>Verification, analytical validation, and clinical validation (V3): the foundation of determining fit-for-purpose for Biometric Monitoring Technologies (BioMeTs)</article-title>. <source>NPJ Digit Med</source>. <year>2020</year>;<volume>3</volume>(<issue>1</issue>):<fpage>55</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41746-020-0260-4</pub-id><pub-id pub-id-type="pmid">32337371</pub-id><pub-id pub-id-type="pmcid">PMC7156507</pub-id></mixed-citation></ref><ref id="aoi250070r18"><label>18</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Zuckerman</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Brown</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Das</surname><given-names>A</given-names></string-name></person-group>. <article-title>Lack of publicly available scientific evidence on the safety and effectiveness of implanted medical devices</article-title>. <source>JAMA Intern Med</source>. <year>2014</year>;<volume>174</volume>(<issue>11</issue>):<fpage>1781</fpage>-<lpage>1787</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamainternmed.2014.4193</pub-id><pub-id pub-id-type="pmid">25265047</pub-id></mixed-citation></ref><ref id="aoi250070r19"><label>19</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Shapiro</surname><given-names>JK</given-names></string-name></person-group>. <article-title>Substantial equivalence premarket review: the right approach for most medical devices</article-title>. <source>Food Drug Law J</source>. <year>2014</year>;<volume>69</volume>(<issue>3</issue>):<fpage>365</fpage>-<lpage>397, i</lpage>.<pub-id pub-id-type="pmid">27382855</pub-id></mixed-citation></ref><ref id="aoi250070r20"><label>20</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Shah</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Olson</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Maurice</surname><given-names>JM</given-names></string-name></person-group>. <article-title>Review of approvals and recalls of US specific medical devices in general and plastic surgery</article-title>. <source>Surg Pract Sci</source>. <year>2023</year>;<volume>12</volume>:<elocation-id>100158</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.sipas.2023.100158</pub-id><pub-id pub-id-type="pmid">39845291</pub-id><pub-id pub-id-type="pmcid">PMC11749930</pub-id></mixed-citation></ref><ref id="aoi250070r21"><label>21</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Ghobadi</surname><given-names>CW</given-names></string-name>, <string-name name-style="western"><surname>Janetos</surname><given-names>TM</given-names></string-name>, <string-name name-style="western"><surname>Tsai</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Welty</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Walter</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>S</given-names></string-name></person-group>. <article-title>Approval-adjusted recall rates of high-risk medical devices from 2002-2016 across food and drug administration device categories</article-title>. <source>Issues Law Med</source>. <year>2019</year>;<volume>34</volume>(<issue>1</issue>):<fpage>77</fpage>-<lpage>92</lpage>.<pub-id pub-id-type="pmid">31179672</pub-id></mixed-citation></ref><ref id="aoi250070r22"><label>22</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Diani</surname><given-names>CA</given-names></string-name>, <string-name name-style="western"><surname>Rock</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Moll</surname><given-names>P</given-names></string-name></person-group>. <article-title>An evaluation of the effectiveness of a risk-based monitoring approach implemented with clinical trials involving implantable cardiac medical devices</article-title>. <source>Clin Trials</source>. <year>2017</year>;<volume>14</volume>(<issue>6</issue>):<fpage>575</fpage>-<lpage>583</lpage>. doi:<pub-id pub-id-type="doi">10.1177/1740774517723589</pub-id><pub-id pub-id-type="pmid">28819983</pub-id></mixed-citation></ref><ref id="aoi250070r23"><label>23</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Cope</surname><given-names>JU</given-names></string-name>, <string-name name-style="western"><surname>Morrison</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Samuels-Reid</surname><given-names>J</given-names></string-name></person-group>. <article-title>Adolescent use of insulin and patient-controlled analgesia pump technology: a 10-year Food and Drug Administration retrospective study of adverse events</article-title>. <source>Pediatrics</source>. <year>2008</year>;<volume>121</volume>(<issue>5</issue>):<fpage>e1133</fpage>-<lpage>e1138</lpage>. doi:<pub-id pub-id-type="doi">10.1542/peds.2007-1707</pub-id><pub-id pub-id-type="pmid">18450857</pub-id></mixed-citation></ref><ref id="aoi250070r24"><label>24</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Everhart</surname><given-names>AO</given-names></string-name>, <string-name name-style="western"><surname>Sen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Stern</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Karaca-Mandic</surname><given-names>P</given-names></string-name></person-group>. <article-title>Association between regulatory submission characteristics and recalls of medical devices receiving 510(k) clearance</article-title>. <source>JAMA</source>. <year>2023</year>;<volume>329</volume>(<issue>2</issue>):<fpage>144</fpage>-<lpage>156</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2022.22974</pub-id><pub-id pub-id-type="pmid">36625811</pub-id><pub-id pub-id-type="pmcid">PMC9857565</pub-id></mixed-citation></ref><ref id="aoi250070r25"><label>25</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Benjamens</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dhunnoo</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Mesk&#243;</surname><given-names>B</given-names></string-name></person-group>. <article-title>The state of artificial intelligence-based FDA-approved medical devices and algorithms: an online database</article-title>. <source>NPJ Digit Med</source>. <year>2020</year>;<volume>3</volume>(<issue>1</issue>):<fpage>118</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41746-020-00324-0</pub-id><pub-id pub-id-type="pmid">32984550</pub-id><pub-id pub-id-type="pmcid">PMC7486909</pub-id></mixed-citation></ref><ref id="aoi250070r26"><label>26</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zaharia</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zou</surname><given-names>J</given-names></string-name></person-group>. <article-title>How is ChatGPT&#8217;s behavior changing over time?</article-title><source>Harvard Data Sci Rev</source>. <year>2024</year>;<volume>6</volume>(<issue>2</issue>). doi:<pub-id pub-id-type="doi">10.1162/99608f92.5317da47</pub-id></mixed-citation></ref><ref id="aoi250070r27"><label>27</label><mixed-citation publication-type="book"><person-group><string-name name-style="western"><surname>Rotalinti</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Tucker</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lonergan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Myles</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Branson</surname><given-names>R</given-names></string-name></person-group>. <part-title>Detecting Drift in Healthcare AI Models Based on Data Availability</part-title>. In: <person-group><string-name name-style="western"><surname>Koprinska</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Mignone</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Guidotti</surname><given-names>R</given-names></string-name>, <etal/></person-group>, eds. <source>Machine Learning and Principles and Practice of Knowledge Discovery in Databases</source>. <publisher-name>Communications in Computer and Information Science. Springer Nature Switzerland</publisher-name>; <year>2023</year>:<fpage>243</fpage>-<lpage>258</lpage>, doi:<pub-id pub-id-type="doi">10.1007/978-3-031-23633-4_17</pub-id></mixed-citation></ref><ref id="aoi250070r28"><label>28</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Mishali</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sheffer</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Mishali</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Negev</surname><given-names>M.</given-names></string-name></person-group><article-title>Understanding variation among medical device reporting sources: a study of the MAUDE database</article-title>. <source>Clin Ther</source>. <year>2024</year>:<elocation-id>S0149-2918(24)00294-7</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.clinthera.2024.10.004</pub-id><pub-id pub-id-type="pmid">39516116</pub-id></mixed-citation></ref><ref id="aoi250070r29"><label>29</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Perez-Downes</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Tseng</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>McConn</surname><given-names>KA</given-names></string-name>, <etal/></person-group>. <article-title>Mitigating bias in clinical machine learning models</article-title>. <source>Curr Treat Options Cardiovasc Med</source>. <year>2024</year>;<volume>26</volume>(<issue>3</issue>):<fpage>29</fpage>-<lpage>45</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11936-023-01032-0</pub-id></mixed-citation></ref></ref-list><notes notes-type="supplementary-material" id="note-AOI250070-1"><supplementary-material id="note-AOI250070-1-s" position="float" content-type="local-data" orientation="portrait"><label>Supplement 1.</label><caption><p>eTable 1. Classification System for Study Designs for AI/ML Devices</p><p>eTable 2. Differences in Characteristics Between Artificial 1 Intelligence/Machine Learning Devices Cleared by the US Food and Drug 2 Administration Over Time, 1995 to 2020 vs 2021 to 2023</p><p>eFigure 1. Trends in Study Design of FDA-Cleared AI/ML Devices, 1995-2023</p><p>eFigure 2. Trends in Timing of Data Collection of FDA-Cleared AI/ML Devices, 1995-2023</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jamahealthforum-e253351-s001.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material position="float" content-type="local-data" orientation="portrait"><label>Supplement 2.</label><caption><p>Characteristics of FDA-Cleared Artificial Intelligence/Machine Learning-Enabled Medical Devices, 1995-2023</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jamahealthforum-e253351-s002.xlsx" position="float" orientation="portrait"/></supplementary-material><supplementary-material position="float" content-type="local-data" orientation="portrait"><label>Supplement 3.</label><caption><p>Data Sharing Statement</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jamahealthforum-e253351-s003.pdf" position="float" orientation="portrait"/></supplementary-material></notes></back></article></pmc-articleset>